<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a case of a previously healthy 31 year old woman diagnosed with Stage IIIA follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treated with fludarabine in combination with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and rituximab who presented seven years after the completion of therapy with CD4 count <z:hpo ids='HP_0000716'>depression</z:hpo>, panhypogammaglobulinema and a history of recurrent <z:e sem="disease" ids="C1398341" disease_type="Disease or Syndrome" abbrv="">sinus infections</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We performed comprehensive immunophenotypic analysis and found her to have only 1.2% switched (<z:mpath ids='MPATH_458'>normal</z:mpath> 21 +/- 8%) and 4.7% non-switched (11 +/- 4%) memory B cells with 92% of B cells belonging to the na√Øve compartment </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously evaluated reconstitution of the B cell compartment during the 6 to 12 month recovery period after treatment with rituximab and found a similar immunophenotypic pattern </plain></SENT>
<SENT sid="3" pm="."><plain>In our patient, this defect was observed seven years after the administration of rituximab in combination with an <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> and <z:chebi fb="0" ids="35584">purine</z:chebi> analog </plain></SENT>
<SENT sid="4" pm="."><plain>The patient was started on monthly intravenous immunoglobulin treatments with complete resolution of her symptoms </plain></SENT>
</text></document>